NO310620B1 - Nye kinazolinforbindelser, farmasöytisk formulering inneholdende slike forbindelser, anvendelse derav, ogfremgangsmåte for deres fremstilling - Google Patents

Nye kinazolinforbindelser, farmasöytisk formulering inneholdende slike forbindelser, anvendelse derav, ogfremgangsmåte for deres fremstilling Download PDF

Info

Publication number
NO310620B1
NO310620B1 NO19981710A NO981710A NO310620B1 NO 310620 B1 NO310620 B1 NO 310620B1 NO 19981710 A NO19981710 A NO 19981710A NO 981710 A NO981710 A NO 981710A NO 310620 B1 NO310620 B1 NO 310620B1
Authority
NO
Norway
Prior art keywords
compound
formula
group
alkyl
quinazoline
Prior art date
Application number
NO19981710A
Other languages
English (en)
Norwegian (no)
Other versions
NO981710D0 (no
NO981710L (no
Inventor
Peter Richard John Hamley
Austen David Pimm
Alan Charles Tinker
Haydn Graham Beaton
Thomas Mcinally
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9521231.2A external-priority patent/GB9521231D0/en
Priority claimed from GBGB9602668.7A external-priority patent/GB9602668D0/en
Priority claimed from GBGB9614386.2A external-priority patent/GB9614386D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO981710D0 publication Critical patent/NO981710D0/no
Publication of NO981710L publication Critical patent/NO981710L/no
Publication of NO310620B1 publication Critical patent/NO310620B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19981710A 1995-10-17 1998-04-16 Nye kinazolinforbindelser, farmasöytisk formulering inneholdende slike forbindelser, anvendelse derav, ogfremgangsmåte for deres fremstilling NO310620B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9521231.2A GB9521231D0 (en) 1995-10-17 1995-10-17 Pharmaceutically active compounds
GBGB9602668.7A GB9602668D0 (en) 1996-02-09 1996-02-09 Pharmaceutically active compounds
GBGB9614386.2A GB9614386D0 (en) 1996-07-09 1996-07-09 Pharmaceutically active compounds
PCT/GB1996/002496 WO1997014686A1 (en) 1995-10-17 1996-10-14 Pharmaceutically active quinazoline compounds

Publications (3)

Publication Number Publication Date
NO981710D0 NO981710D0 (no) 1998-04-16
NO981710L NO981710L (no) 1998-06-03
NO310620B1 true NO310620B1 (no) 2001-07-30

Family

ID=27267949

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981710A NO310620B1 (no) 1995-10-17 1998-04-16 Nye kinazolinforbindelser, farmasöytisk formulering inneholdende slike forbindelser, anvendelse derav, ogfremgangsmåte for deres fremstilling

Country Status (20)

Country Link
US (1) US5883102A (cs)
EP (1) EP0858451A1 (cs)
JP (1) JPH11513679A (cs)
KR (1) KR19990064276A (cs)
CN (1) CN1204327A (cs)
AR (1) AR004219A1 (cs)
AU (1) AU704133B2 (cs)
BR (1) BR9610988A (cs)
CA (1) CA2235304A1 (cs)
CZ (1) CZ119398A3 (cs)
EE (1) EE9800116A (cs)
HU (1) HUP9900028A3 (cs)
IS (1) IS4715A (cs)
NO (1) NO310620B1 (cs)
NZ (1) NZ319673A (cs)
PL (1) PL326353A1 (cs)
SK (1) SK45898A3 (cs)
TR (1) TR199800697T2 (cs)
WO (1) WO1997014686A1 (cs)
ZA (1) ZA968767B (cs)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9702534D0 (sv) 1997-07-01 1997-07-01 Astra Pharma Prod Compounds
DE19731783A1 (de) * 1997-07-24 1999-01-28 Bayer Ag Verfahren zur Herstellung von N-(5-Amino-2-cyano-4-fluor-phenyl)-sulfonamiden und neue Zwischenprodukte
AU4562799A (en) 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
SE9802333D0 (sv) 1998-06-29 1998-06-29 Astra Pharma Prod Novel combination
WO2000013709A2 (en) * 1998-09-08 2000-03-16 Monsanto Company Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
SE0000477D0 (sv) * 2000-02-14 2000-02-14 Astrazeneca Canada Inc Novel compounds
US6482829B2 (en) * 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US6534220B2 (en) 2000-12-29 2003-03-18 3M Innovative Properties Company High-boiling electrolyte solvent
WO2002076953A1 (en) 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
US7470709B2 (en) 2002-08-23 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
AU2003263323A1 (en) * 2002-09-07 2004-03-29 Celltech R And D Limited Quinazolinone derivatives
TWI367759B (en) * 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
MXPA06010900A (es) * 2004-03-26 2007-02-21 Methylgene Inc Inhibidores de histona desacetilasa.
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2006244068B9 (en) * 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
TW200804290A (en) * 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007138613A2 (en) * 2006-05-25 2007-12-06 Vittal Mallya Scientific Research Foundation A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride
WO2007138612A2 (en) * 2006-05-25 2007-12-06 Vittal Mallya Scientific Research Foundation A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4- yl]-(3-ethynylphenyl)amine hydrochloride
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
TW200902526A (en) 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
DE102007038250A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
EA022669B1 (ru) 2008-07-08 2016-02-29 Инсайт Холдингс Корпорейшн 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
EP2511268B2 (en) 2009-12-11 2021-02-17 Shionogi & Co., Ltd. Oxazine derivative
WO2011077726A1 (ja) * 2009-12-24 2011-06-30 塩野義製薬株式会社 ４－アミノ－１，３－チアジンまたはオキサジン誘導体
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
UA111854C2 (uk) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090044A1 (es) * 2011-12-21 2014-10-15 Novira Therapeutics Inc Agentes antivirales para la hepatitis b
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
JP6461953B2 (ja) 2013-11-08 2019-01-30 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ インドールアミン２，３−ジオキシゲナーゼ阻害剤の合成のためのプロセス
WO2025024605A1 (en) * 2023-07-25 2025-01-30 University Of Florida Research Foundation, Incorporated Rev-erb antagonists

Also Published As

Publication number Publication date
PL326353A1 (en) 1998-09-14
CA2235304A1 (en) 1997-04-24
TR199800697T2 (xx) 1998-07-21
NO981710D0 (no) 1998-04-16
US5883102A (en) 1999-03-16
WO1997014686A1 (en) 1997-04-24
JPH11513679A (ja) 1999-11-24
HUP9900028A2 (hu) 1999-04-28
MX9802926A (cs) 1998-08-01
CN1204327A (zh) 1999-01-06
EE9800116A (et) 1998-10-15
AU704133B2 (en) 1999-04-15
NO981710L (no) 1998-06-03
ZA968767B (en) 1997-04-17
AU7224396A (en) 1997-05-07
EP0858451A1 (en) 1998-08-19
NZ319673A (en) 2000-06-23
CZ119398A3 (cs) 1998-09-16
SK45898A3 (en) 1999-01-11
BR9610988A (pt) 1999-04-06
IS4715A (is) 1998-04-15
AR004219A1 (es) 1998-11-04
KR19990064276A (ko) 1999-07-26
HUP9900028A3 (en) 1999-11-29

Similar Documents

Publication Publication Date Title
NO310620B1 (no) Nye kinazolinforbindelser, farmasöytisk formulering inneholdende slike forbindelser, anvendelse derav, ogfremgangsmåte for deres fremstilling
AU2009320683B2 (en) Pyridine-3-carboxyamide derivative
CA2646678C (en) Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US6965036B2 (en) Intermediates for guanidine mimics as factor Xa inhibitors
JP4394442B2 (ja) 抗炎症剤として有用なスピロ−ヒダントイン化合物
CA2647677C (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
DE69921358T2 (de) Stickstoffhaltige heterobicyclen als faktor-xa-hemmer
JP4422800B2 (ja) 心臓循環系疾患の処置のための新規な置換ピラゾール誘導体
JP6601818B2 (ja) ポリエンマクロライド誘導体
HRP20020327A2 (en) Alkylamino substited bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
SK48799A3 (en) New heterocyclylmethyl-substituted pyrazol derivates and their use for treating cardiovascular diseases
CA2961186A1 (en) Tricyclic derivative
CN110997661A (zh) 环丙基脲甲酰肽2受体和甲酰肽1受体激动剂
JP2011516398A (ja) Ｎｐｙ−ｙ５アンタゴニストとしてのヘテロスピロ−デカン残基を有するベンズイミダゾール誘導体
MX2013005773A (es) Inhibidores de kat ii.
AU2004212435A1 (en) Process for preparing pyrrolotriazine kinase inhibitors
KR20010006143A (ko) 화합물
Lopes et al. Diels–Alder reactions of 3-(1H-tetrazol-5-yl)-nitrosoalkenes: Synthesis of functionalized 5-(substituted)-1H-tetrazoles
AU2004200420A1 (en) Inhibitor of cyclooxygenase
JPH0940673A (ja) ヒダントイン誘導体、これらの製造方法、及びこれらを有効成分とする除草剤
MXPA98002926A (en) Pharmaceutically active quinazoline compounds
NO874780L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolo-benzimidazol-derivater.
KR20250019219A (ko) Pd-l1 억제제로서 신규한 인돌린 유도체
US20080167302A1 (en) Peptide Deformylase Inhibitors
AU2002334771A1 (en) Spiro-hydantoin compounds useful as anti-inflammatory agents

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2003